SG11202003820VA - External preparation for treating trichophytosis unguium - Google Patents

External preparation for treating trichophytosis unguium

Info

Publication number
SG11202003820VA
SG11202003820VA SG11202003820VA SG11202003820VA SG11202003820VA SG 11202003820V A SG11202003820V A SG 11202003820VA SG 11202003820V A SG11202003820V A SG 11202003820VA SG 11202003820V A SG11202003820V A SG 11202003820VA SG 11202003820V A SG11202003820V A SG 11202003820VA
Authority
SG
Singapore
Prior art keywords
external preparation
treating
unguium
trichophytosis unguium
treating trichophytosis
Prior art date
Application number
SG11202003820VA
Other languages
English (en)
Inventor
Nobuyuki Natori
Hiroyuki Takabe
Takashi Ishimaru
Hiroshi Iseki
Keiichi Karasawa
Original Assignee
Kaken Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kaken Pharmaceutical Co Ltd filed Critical Kaken Pharmaceutical Co Ltd
Publication of SG11202003820VA publication Critical patent/SG11202003820VA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Dermatology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
SG11202003820VA 2017-10-30 2018-10-29 External preparation for treating trichophytosis unguium SG11202003820VA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2017209136 2017-10-30
PCT/JP2018/040047 WO2019088005A1 (fr) 2017-10-30 2018-10-29 Préparation externe destinée au traitement de la trichophytie unguéale

Publications (1)

Publication Number Publication Date
SG11202003820VA true SG11202003820VA (en) 2020-05-28

Family

ID=66333195

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202003820VA SG11202003820VA (en) 2017-10-30 2018-10-29 External preparation for treating trichophytosis unguium

Country Status (14)

Country Link
US (1) US20210213002A1 (fr)
EP (1) EP3705136A4 (fr)
JP (2) JP6582158B1 (fr)
KR (1) KR20200081432A (fr)
CN (1) CN111295202B (fr)
AU (1) AU2018358372A1 (fr)
BR (1) BR112020008282A2 (fr)
CA (1) CA3081163A1 (fr)
IL (1) IL274100B2 (fr)
MX (1) MX2020004491A (fr)
RU (1) RU2020117569A (fr)
SG (1) SG11202003820VA (fr)
TW (1) TWI789448B (fr)
WO (1) WO2019088005A1 (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20220119363A (ko) 2019-12-24 2022-08-29 가껭세이야꾸가부시기가이샤 에피나코나졸을 함유하는 의약
KR102217617B1 (ko) * 2020-08-14 2021-02-19 비엘엔에이치 주식회사 백선의 예방 또는 치료용 약학적 조성물
JP2022547755A (ja) * 2020-08-14 2022-11-16 ビーエルアンドエイチ カンパニー，リミテッド 白癬を防止又は処置するための医薬組成物

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4514385A (en) * 1981-10-05 1985-04-30 Alcon Laboratories, Inc. Anti-acne compositions
JPS58162514A (ja) * 1982-03-19 1983-09-27 Sumitomo Chem Co Ltd 外用ゲル製剤
AU618517B2 (en) * 1986-12-23 1992-01-02 Eugene J. Van Scott Additives enhancing topical actions of therapeutic agents
NZ275615A (en) * 1993-09-29 1996-11-26 Alza Corp Oxybutynin composition containing monoglyceride and lactate ester as permeability enhancers; device for transdermal administration of oxybutynin
WO2000015202A2 (fr) * 1998-09-10 2000-03-23 Ipr-Institute For Pharmaceutical Research Ag Produits pour l'application locale
US7384650B2 (en) * 1999-11-24 2008-06-10 Agile Therapeutics, Inc. Skin permeation enhancement composition for transdermal hormone delivery system
US8048919B2 (en) * 2004-06-28 2011-11-01 Archer Daniels Midland Company Use of ethyl lactate as an excipient for pharmaceutical compositions
JP5061519B2 (ja) 2006-07-12 2012-10-31 大正製薬株式会社 抗真菌剤含有ｏ／ｗエマルション組成物
KR101184834B1 (ko) 2007-08-27 2012-09-20 니혼노야쿠가부시키가이샤 진균성 피부염용제
NL2003711C2 (en) * 2009-10-27 2011-04-28 Shield Mark B V Aqueous composition for topical application, method of preparation, uses and device.
NL2003786C2 (en) * 2009-11-11 2010-07-30 Medner B V COMPOSITION FOR TOPICAL APPLICATION, USES THEREOF, APPLICATOR DEVICE AND KIT OF PARTS.
US8889727B2 (en) * 2011-01-30 2014-11-18 Meiji Seika Pharma Co., Ltd. Topical antifungal agent
MX353713B (es) * 2011-11-04 2018-01-24 Agile Therapeutics Inc Composiciones de administracion dermica y metodos.
IN2015DN02377A (fr) * 2012-09-14 2015-09-04 Pola Pharma Inc
RU2694758C2 (ru) * 2012-12-20 2019-07-16 Раджив Бхушан Антимикробные композиции
JP6308137B2 (ja) * 2012-12-28 2018-04-11 大正製薬株式会社 皮膚適用製剤
CN103142458B (zh) * 2013-01-22 2015-09-09 莱普德制药有限公司 无成瘾性镇痛缓释递药系统的组方与制备方法
KR102612453B1 (ko) * 2013-11-22 2023-12-08 다우 파마슈티컬 사이언시즈, 인코포레이티드 항­감염 방법，조성물，및 장치
JP5623671B1 (ja) * 2014-07-23 2014-11-12 株式会社ポーラファルマ ルリコナゾールを含有する製剤の評価方法及び指標物質
US10647675B2 (en) * 2015-09-18 2020-05-12 Kaken Pharmaceutical Co., Ltd. Biaryl derivative and medicine containing same
JP2017209136A (ja) 2016-05-23 2017-11-30 澁谷工業株式会社 電子線殺菌装置

Also Published As

Publication number Publication date
MX2020004491A (es) 2020-08-13
TWI789448B (zh) 2023-01-11
JP2020011967A (ja) 2020-01-23
KR20200081432A (ko) 2020-07-07
CN111295202A (zh) 2020-06-16
WO2019088005A1 (fr) 2019-05-09
AU2018358372A1 (en) 2020-05-28
RU2020117569A3 (fr) 2021-12-01
TW201922247A (zh) 2019-06-16
EP3705136A1 (fr) 2020-09-09
JPWO2019088005A1 (ja) 2019-11-14
JP6582158B1 (ja) 2019-09-25
CN111295202B (zh) 2022-07-08
CA3081163A1 (fr) 2019-05-09
RU2020117569A (ru) 2021-12-01
US20210213002A1 (en) 2021-07-15
IL274100B2 (en) 2023-06-01
BR112020008282A2 (pt) 2020-10-20
EP3705136A4 (fr) 2021-08-18
IL274100A (en) 2020-06-30

Similar Documents

Publication Publication Date Title
HK1253073A1 (zh) 抗真菌化合物
HK1258862A1 (zh) 抗真菌化合物方法
RS63566B1 (sr) Antifungalna jedinjenja i procesi izrade
EP3119755A4 (fr) Procédé de préparation d'un composé antifongique
PL3119745T3 (pl) Sposób wytwarzania związku przeciwgrzybiczego
EP3119754A4 (fr) Préparation d'un composé antifongique
IL252912B (en) Processes for preparing oxathiazine-like compounds
EP3119748A4 (fr) Procédé de préparation d'un composé antifongique
EP3119771A4 (fr) Procédé associé à un composé antifongique
EP3119746A4 (fr) Procédé de préparation d'un composé antifongique
EP3119764A4 (fr) Procédé de préparation d'un composé antifongique
EP3119749A4 (fr) Procédé de préparation de composé antifongique
HK1255114A1 (zh) 抗真菌劑
HK1247097A1 (zh) 用於製備氟酮內酯的方法
IL274100A (en) An external preparation for the treatment of fungal infection in the hornets
PT3096615T (pt) Composição antifúngica
IL253147A0 (en) Pyrazole compounds
ZA201704292B (en) Pyrazole compounds
GB201522534D0 (en) Antifungal composition/treatment
GB201505043D0 (en) Antifungal composition/treatment
GB201505891D0 (en) Antifungal agents